Thyroid-associated ophthalmopathy (TAO) is an inflammatory eye disease associated with thyroid autoimmune disorder.The traditional treatments have yielded limited efficacy but with some side effects.Recently,researches have shown that some new immunosupressants may be used for the treatment of TAO with significantly improved symptoms,and reduction in clinical activity score.